Impact of comorbidities on the average length of stay and mortality of COVID-19 patients in a hospital: In India

被引:0
|
作者
Rudresh, S. A. [1 ,5 ]
Madaan, Nirupam [2 ]
Suneja, Manish [3 ]
Manoharan, Nallaiah [4 ]
机构
[1] SDM Coll Med Sci & Hosp, Dept Hosp Adm, Dharward, India
[2] All India Inst Med Sci, Dept Hosp Adm, New Delhi, India
[3] All India Inst Med Sci, Dept Gen Med, New Delhi, India
[4] All India Inst Med Sci, New Delhi, India
[5] SDM Coll Med Sci & Hosp, Dept Hosp Adm, Dharwad 580009, India
关键词
Corona virus; comorbidity; average length of stay; mortality; pandemic;
D O I
10.1080/20479700.2023.2217564
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
ObjectiveTo estimate the length of stay and proportional mortality in COVID patients in a COVID-dedicated hospital.MethodsA retrospective record review was done using medical records of COVID-19 in-patients, capturing the demographic, clinical, and laboratory details of admitted COVID patients, including serial samples for RTPCR/CBNAAT for Coronavirus. These details from electronic medical records were compared and collated for patients of different comorbidities to arrive at the average length of stay and case fatality rate and time duration for patients to turn COVID-negative.ResultsPatients with Diabetes Mellitus (DM) had the highest Average Length of Stay (ALS) of 12.09 days in the hospital followed by patients with Hypertension (11.5 days). Patients without any comorbidities had ALS of 8.8 days. A combination of HTN, DM, coronary artery disease (CAD), and chronic kidney disease (CKD) had the highest ALS of 14.5 days. The average duration for patients to test negative is 16 days for patients without any comorbidities. The average duration between the first symptom and the negative test is the longest for DM (21 days) followed by HTN (19.5 days), cancer (19 days), and obesity (16 days). Among the 731 people who died in the observed time, the proportional mortality rate was highest with HTN (10.80%) followed by carcinoma (7.66%) and DM (6.56%), 32.55% had a combination of two or more comorbidities. 33.70% deceased didn't have any comorbidities.ConclusionThe COVID-19 pandemic has highlighted the importance of preparing for future outbreaks and sudden increases in cases. Based on our findings, we recommend Hospital administrators have a comprehensive approach to planning for the future, considering all relevant factors, including the epidemiology of the disease, the average length of stay, and mortality rates, to ensure that their hospitals are equipped to provide high-quality care to all patients.
引用
收藏
页码:586 / 591
页数:6
相关论文
共 50 条
  • [41] Targeting average length of hospital stay as a control measure to decrease COVID-19 hospital-acquired infection in surgical cancer patients
    Sarah S. Nasr
    Ghada M. Sherif
    Maha Abdel Wahab
    Hatem Aboelkasem
    Journal of the Egyptian National Cancer Institute, 35
  • [42] Targeting average length of hospital stay as a control measure to decrease COVID-19 hospital-acquired infection in surgical cancer patients
    Nasr, Sarah S.
    Sherif, Ghada M.
    Wahab, Maha Abdel
    Aboelkasem, Hatem
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2023, 35 (01)
  • [43] Comorbidities and Factors Determining Medical Expenses and Length of Stay for Admitted COVID-19 Patients in Korea
    Jang, Su Yeon
    Seon, Jeong-Yeon
    Yoon, Seok-Jun
    Park, So-Youn
    Lee, Seung Heon
    Oh, In-Hwan
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2021, 14 : 2021 - 2033
  • [44] Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs
    Vernaz, Nathalie
    Agoritsas, Thomas
    Calmy, Alexandra
    Gayet-Ageron, Angele
    Gold, Gabriel
    Perrier, Arnaudg
    Picard, Fabienne
    Prendki, Virginie
    Reny, Jean-Luc
    Samer, Caroline
    Stirnemann, Jerome
    Vetter, Pauline
    Zanella, Marie-Celine
    Zekry, Dina
    Baggio, Stephanien
    SWISS MEDICAL WEEKLY, 2020, 150
  • [45] COVID-19 pandemic and management on hospital length of stay: A review
    Ahdollahi, Fatemeh
    Ghanyan, Seilan
    Asadi, Farkhondeh
    HEALTHCARE IN LOW-RESOURCE SETTINGS, 2021, 9 (01)
  • [46] Birth Hospital Length of Stay and Rehospitalization During COVID-19
    Handley, Sara C.
    Gallagher, Kieran
    Breden, Amy
    Lindgren, Eric
    Lo, Justin Y.
    Son, Moeun
    Murosko, Daria
    Dysart, Kevin
    Lorch, Scott A.
    Greenspan, Jay
    Culhane, Jennifer F.
    Burris, Heather H.
    PEDIATRICS, 2022, 149 (01)
  • [47] Qualitative Subgenomic RNA to Monitor the Response to Remdesivir in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): Impact on the Length of Hospital Stay and Mortality
    Alonso-Navarro, Rodrigo
    Cuesta, Genoveva
    Santos, Marta
    Cardozo, Celia
    Rico, Veronica
    Garcia-Pouton, Nicole
    Tuset, Montse
    Bodro, Marta
    Morata, Laura
    Puerta-Alcalde, Pedro
    Herrera, Sabina
    Soria, Dafne
    Aldea, Marta
    Mensa, Josep
    Antonio Martinez, Jose
    Del Rio, Ana
    Vila, Jordi
    Garcia, Felipe
    Garcia-Vidal, Carolina
    Angeles Marcos, M.
    Soriano, Alex
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (01) : 32 - 38
  • [48] Impact of comorbidities on mortality in hospitalized patients with COVID-19: An experience from Iran
    Toofan, Firooz
    Hosseini, Seyed Mojtaba
    Alimohammadzadeh, Khalil
    Jafari, Mehrnoosh
    Bahadori, Mohammadkarim
    JOURNAL OF EDUCATION AND HEALTH PROMOTION, 2021, 10 (01)
  • [49] Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
    Akbari, Abolfazl
    Razmi, Mahya
    Sedaghat, Alireza
    Alavi Dana, Seyyed Mohammad Matin
    Amiri, Mahdi
    Halvani, Ali Mohammad
    Yazdani, Soroush
    Sahab-Negah, Sajad
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2022, 20 (04) : 585 - 609
  • [50] Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients
    LaClair, Heather J.
    Khosrodad, Nadia
    Sule, Anupam A.
    Koehler, Tracy
    Krishnamoorthy, Geetha
    VASCULAR PHARMACOLOGY, 2021, 141